Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer
May 05, 2020 08:05 ET
|
Guardant Health, Inc.
Incomplete testing fails to meet current medical guideline standards, placing more than 80 percent1 of patients at increased risk of receiving a less effective treatment REDWOOD CITY, Calif.,...
Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection Program
May 02, 2020 10:35 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., May 02, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) presents new data at Digestive Disease Week (DDW) 2020 that highlights the performance of its LUNAR-2 assay...
Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020
April 30, 2020 16:03 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the first quarter 2020 after market close on...
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
April 09, 2020 08:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Many women with metastatic hormone receptor-positive (HR+) breast cancer have experienced improved clinical outcomes with the recent...
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook
February 24, 2020 16:03 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its...
Guardant Health to Participate in Upcoming Investor Conferences
February 12, 2020 18:15 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in two upcoming investor conferences. Guardant Health’s...
Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
February 10, 2020 16:05 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the fourth quarter and full year 2019 after market...
Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
January 21, 2020 08:30 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) a leading precision oncology company, has appointed Kumud Kalia as the company’s new Chief Information...
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
January 13, 2020 08:30 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announces a strategic collaboration to develop and help support commercialization of a blood-based...
Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer
January 12, 2020 20:00 ET
|
Guardant Health, Inc.
REDWOOD CITY, Calif. and PITTSBURGH, Pa., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and NRG Oncology, a National Cancer Institute...